Endogena Therapeutics-preview

Endogena

Endogena Therapeutics

Private

ZurichHealthcare & Life Scienceshttps://endogena.com/

Last Round

Series A

Extension

Dec 13, 2021

Total Funding Raised

$29M

Company Overview

Endogena Therapeutics is a clinical-stage biotech company that discovers and develops first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs, with a focus on degenerative diseases of the eye.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI, Precision Medicine

Business Model

B2B2C

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

regenerative medicineRetinitis PigmentosaRPstem cell therapysmall molecule therapeuticsendogenous stem cell activationgene-independent therapyretinal disease treatmentGeographic Atrophyvision restorationAge-related Macular DegenerationAMDphotoreceptor regenerationtissue regenerationclinical-stage biotechnologyOrphan Drug DesignationAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Endogena Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Endogena Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series A Extension	Dec 13, 2021
Series A	Jan 26, 2021

View all Funding Rounds

Endogena Therapeutics Investors

Notable investors and investment history

Investor	Rounds
DEFTA Partners	Series A Extension, Series A

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Nov 7, 2025
Monthly visitors increased 41% MoM.
Dec 13, 2021
$21M round led by Centenara Labs.

View all signals

Endogena Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Endogena Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Endogena Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersZurich

Employee Range3

Year Founded2016

Last FundingDec 13, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.